Skip to main content
Top
Published in: International Journal of Hematology 5/2017

01-05-2017 | Original Article

Spousal hematopoietic stem cell transplantation

Authors: Kazuhiro Ikegame, Katsuji Kaida, Satoshi Yoshihara, Kyoko Yoshihara, Shinichi Ishii, Takayuki Inoue, Masaya Okada, Hiroya Tamaki, Toshihiro Soma, Yasushi Kusunoki, Hiroto Kojima, Hiroh Saji, Hiroyasu Ogawa

Published in: International Journal of Hematology | Issue 5/2017

Login to get access

Abstract

We report a pilot series of five patients who received stem cell transplantation (SCT) from a spouse for post-transplant relapse or rejection. The inclusion criterion regarding HLA disparities was three or fewer antigen mismatches in the graft-versus-host direction at the HLA-A, B, and DR loci. Four patients received spousal SCT as a third transplant attempt after post-transplant relapse and one as rescue for graft rejection. The reduced intensity conditioning (RIC) regimen consisted of fludarabine, melphalan, and anti-thymocyte globulin (ATG) with 3 Gy of total body irradiation (TBI) for relapse cases and ATG plus 4 Gy of TBI for the rejection case. Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus, methylprednisolone, and mycophenolate mofetil. Peripheral blood stem cells were transplanted. Granulocyte engraftment was achieved in all cases between days 9 and 11 (median, 10) with complete spousal chimerism. In three of the five patients, no acute GVHD was observed, while one case developed grade III GVHD and one case grade IV. All four patients evaluable for the anti-leukemic effect achieved complete remission; however, all relapsed between 106 and 334 day post-transplant, and died between days 152 and 548. We suggest that spousal SCT can be performed as a repetitive SCT using a RIC regimen with low-dose ATG and steroid-containing GVHD prophylaxis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med. 1995;333:333–6.CrossRefPubMed Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med. 1995;333:333–6.CrossRefPubMed
2.
go back to reference McCashland TM, Wright TL, Donovan JP, Schafer DF, Sorrell MF, Heffron TG, et al. Low incidence of intraspousal transmission of hepatitis C virus after liver transplantation. Liver Transpl Surg. 1995;1:358–61.CrossRefPubMed McCashland TM, Wright TL, Donovan JP, Schafer DF, Sorrell MF, Heffron TG, et al. Low incidence of intraspousal transmission of hepatitis C virus after liver transplantation. Liver Transpl Surg. 1995;1:358–61.CrossRefPubMed
3.
go back to reference Tang S, Lui SL, Lo CY, Lo WK, Cheng IK, Lai KN, Chan TM. Spousal renal donor transplantation in Chinese subjects: a 10 year experience from a single centre. Nephrol Dial Transplant. 2004;19:203–6.CrossRefPubMed Tang S, Lui SL, Lo CY, Lo WK, Cheng IK, Lai KN, Chan TM. Spousal renal donor transplantation in Chinese subjects: a 10 year experience from a single centre. Nephrol Dial Transplant. 2004;19:203–6.CrossRefPubMed
4.
go back to reference Lee SH, Jeong JS, Ha HS, No MJ, Hong JJ, Kwon JS, et al. Decision-related factors and attitudes toward donation in living related liver transplantation: ten-year experience. Transplant Proc. 2005;37:1081–4.CrossRefPubMed Lee SH, Jeong JS, Ha HS, No MJ, Hong JJ, Kwon JS, et al. Decision-related factors and attitudes toward donation in living related liver transplantation: ten-year experience. Transplant Proc. 2005;37:1081–4.CrossRefPubMed
5.
go back to reference Rudow DL, Chariton M, Sanchez C, Chang S, Serur D, Brown RS Jr. Kidney and liver living donors: a comparison of experiences. Prog Transplant. 2005;15:185–91.CrossRefPubMed Rudow DL, Chariton M, Sanchez C, Chang S, Serur D, Brown RS Jr. Kidney and liver living donors: a comparison of experiences. Prog Transplant. 2005;15:185–91.CrossRefPubMed
6.
go back to reference Roozbeh J, Mehdizadeh AR, Izadfar MA, Razmkon A, Salahi H, Malek-Hosseini SA. Comparison of spousal with other donor groups: study of a single center. Transplant Proc. 2006;38:562–3.CrossRefPubMed Roozbeh J, Mehdizadeh AR, Izadfar MA, Razmkon A, Salahi H, Malek-Hosseini SA. Comparison of spousal with other donor groups: study of a single center. Transplant Proc. 2006;38:562–3.CrossRefPubMed
7.
go back to reference Trotter JF, Wisniewski KA, Terrault NA, Everhart JE, Kinkhabwala M, Weinrieb RM, et al. Outcomes of donor evaluation in adult-to-adult living donor liver transplantation. Hepatology. 2007;46:1476–84.CrossRefPubMedPubMedCentral Trotter JF, Wisniewski KA, Terrault NA, Everhart JE, Kinkhabwala M, Weinrieb RM, et al. Outcomes of donor evaluation in adult-to-adult living donor liver transplantation. Hepatology. 2007;46:1476–84.CrossRefPubMedPubMedCentral
8.
go back to reference Sakai K, Okamoto M, Suzuki T, Yoshizawa A, Nobori S, Ushigome H, et al. The excellent results of spousal kidney transplantation: experience in a Japanese single center. Transplant Proc. 2008;40:2118–20.CrossRefPubMed Sakai K, Okamoto M, Suzuki T, Yoshizawa A, Nobori S, Ushigome H, et al. The excellent results of spousal kidney transplantation: experience in a Japanese single center. Transplant Proc. 2008;40:2118–20.CrossRefPubMed
9.
go back to reference Ishikawa N, Yagisawa T, Sakuma Y, Fujiwara T, Nukui A, Yashi M, et al. Transplantation of ABO-incompatible and living unrelated donor-recipient combinations. Transplant Proc. 2008;40:2292–3.CrossRefPubMed Ishikawa N, Yagisawa T, Sakuma Y, Fujiwara T, Nukui A, Yashi M, et al. Transplantation of ABO-incompatible and living unrelated donor-recipient combinations. Transplant Proc. 2008;40:2292–3.CrossRefPubMed
10.
go back to reference Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320:197–204.CrossRefPubMed Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320:197–204.CrossRefPubMed
11.
go back to reference Anasetti C. The role of the immunogenetics laboratory in marrow transplantation. Arch Pathol Lab Med. 1991;115:288–92.PubMed Anasetti C. The role of the immunogenetics laboratory in marrow transplantation. Arch Pathol Lab Med. 1991;115:288–92.PubMed
12.
go back to reference Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186–93.CrossRefPubMed Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186–93.CrossRefPubMed
13.
go back to reference Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107:3065–73.CrossRefPubMed Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107:3065–73.CrossRefPubMed
14.
go back to reference Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–50.CrossRefPubMedPubMedCentral Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–50.CrossRefPubMedPubMedCentral
15.
go back to reference Ikegame K, Tanji Y, Kitai N, Tamaki H, Kawakami M, Fujioka T, et al. Successful treatment of refractory T-cell acute lymphoblastic leukemia by unmanipulated stem cell transplantation from an HLA 3-loci mismatched (haploidentical) sibling. Bone Marrow Transplant. 2003;31:507–10.CrossRefPubMed Ikegame K, Tanji Y, Kitai N, Tamaki H, Kawakami M, Fujioka T, et al. Successful treatment of refractory T-cell acute lymphoblastic leukemia by unmanipulated stem cell transplantation from an HLA 3-loci mismatched (haploidentical) sibling. Bone Marrow Transplant. 2003;31:507–10.CrossRefPubMed
16.
go back to reference Ikegame K, Mukouchi C, Kunitomi A, Konaka Y, Kawakami M, Nishida S, et al. Successful treatment of bcr/abl-positive acute mixed lineage leukemia by unmanipulated bone marrow transplantation from an HLA-haploidentical (3-antigen-mismatched) cousin. Bone Marrow Transplant. 2003;31:1165–8 (Int J Hematol. 2004;80:453–7).CrossRefPubMed Ikegame K, Mukouchi C, Kunitomi A, Konaka Y, Kawakami M, Nishida S, et al. Successful treatment of bcr/abl-positive acute mixed lineage leukemia by unmanipulated bone marrow transplantation from an HLA-haploidentical (3-antigen-mismatched) cousin. Bone Marrow Transplant. 2003;31:1165–8 (Int J Hematol. 2004;80:453–7).CrossRefPubMed
17.
go back to reference Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T, et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant. 2006;12:1073–84.CrossRefPubMed Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T, et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant. 2006;12:1073–84.CrossRefPubMed
18.
go back to reference Ogawa H, Ikegame K, Kaida K, Yoshihara S, Fujioka T, Taniguchi Y, et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Exp Hematol. 2008;36:1–8.CrossRefPubMed Ogawa H, Ikegame K, Kaida K, Yoshihara S, Fujioka T, Taniguchi Y, et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Exp Hematol. 2008;36:1–8.CrossRefPubMed
19.
go back to reference Ikegame K, Yoshida T, Yoshihara S, Daimon T, Shimizu H, Maeda Y, et al. Unmanipulated haploidentical RIST using fludarabine, busulfan, low- dose ATG and steroid for patients in non-CR or at high risk of relapse: a prospective multicenter phase I/II study in Japan. Biol Blood Marrow Transplant. 2015;21:1495–505.CrossRefPubMed Ikegame K, Yoshida T, Yoshihara S, Daimon T, Shimizu H, Maeda Y, et al. Unmanipulated haploidentical RIST using fludarabine, busulfan, low- dose ATG and steroid for patients in non-CR or at high risk of relapse: a prospective multicenter phase I/II study in Japan. Biol Blood Marrow Transplant. 2015;21:1495–505.CrossRefPubMed
20.
go back to reference Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Stanghellini MT, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361:478–88.CrossRefPubMed Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Stanghellini MT, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361:478–88.CrossRefPubMed
21.
go back to reference Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412–5.CrossRefPubMed Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412–5.CrossRefPubMed
22.
go back to reference Duffner UA, Maeda Y, Cooke KR, Reddy P, Ordemann R, Liu C, et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol. 2004;172:7393–8.CrossRefPubMed Duffner UA, Maeda Y, Cooke KR, Reddy P, Ordemann R, Liu C, et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol. 2004;172:7393–8.CrossRefPubMed
23.
go back to reference Taniguchi Y, Yoshihara S, Hoshida Y, Inoue T, Fujioka T, Ikegame K, et al. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor. Exp Hematol. 2008;36:1216–25.CrossRefPubMed Taniguchi Y, Yoshihara S, Hoshida Y, Inoue T, Fujioka T, Ikegame K, et al. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor. Exp Hematol. 2008;36:1216–25.CrossRefPubMed
24.
go back to reference Kanda J, Saji H, Fukuda T, Kobayashi T, Miyamura K, Eto T, et al. Related transplantation with HLA-1 Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation: a nationwide retrospective study. Blood. 2012;119:2409–16.CrossRefPubMed Kanda J, Saji H, Fukuda T, Kobayashi T, Miyamura K, Eto T, et al. Related transplantation with HLA-1 Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation: a nationwide retrospective study. Blood. 2012;119:2409–16.CrossRefPubMed
25.
go back to reference Park Y, Cheong JW, Park MH, Kim MS, Kim JS, Kim HS. Effect of major histocompatibility complex haplotype matching by C4 and MICA genotyping on acute graft versus host disease in unrelated hematopoietic stem cell transplantation. Hum Immunol. 2016;77:176–83.CrossRefPubMed Park Y, Cheong JW, Park MH, Kim MS, Kim JS, Kim HS. Effect of major histocompatibility complex haplotype matching by C4 and MICA genotyping on acute graft versus host disease in unrelated hematopoietic stem cell transplantation. Hum Immunol. 2016;77:176–83.CrossRefPubMed
26.
go back to reference Jöris MM, Lankester AC, von dem Borne PA, Kuball J, Bierings M, Cornelissen JJ, et al. The impact of frequent HLA haplotypes in high linkage disequilibrium on donor search and clinical outcome after unrelated haematopoietic SCT. Bone Marrow Transplant. 2013;48:483–90.CrossRefPubMed Jöris MM, Lankester AC, von dem Borne PA, Kuball J, Bierings M, Cornelissen JJ, et al. The impact of frequent HLA haplotypes in high linkage disequilibrium on donor search and clinical outcome after unrelated haematopoietic SCT. Bone Marrow Transplant. 2013;48:483–90.CrossRefPubMed
27.
go back to reference Yoshihara S, Maruya E, Taniguchi K, Kaida K, Kato R, Inoue T, et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant. 2012;47:508–15.CrossRefPubMed Yoshihara S, Maruya E, Taniguchi K, Kaida K, Kato R, Inoue T, et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant. 2012;47:508–15.CrossRefPubMed
Metadata
Title
Spousal hematopoietic stem cell transplantation
Authors
Kazuhiro Ikegame
Katsuji Kaida
Satoshi Yoshihara
Kyoko Yoshihara
Shinichi Ishii
Takayuki Inoue
Masaya Okada
Hiroya Tamaki
Toshihiro Soma
Yasushi Kusunoki
Hiroto Kojima
Hiroh Saji
Hiroyasu Ogawa
Publication date
01-05-2017
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 5/2017
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2168-y

Other articles of this Issue 5/2017

International Journal of Hematology 5/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine